IGF2 and neoplasm: DNA methylation-dependent and -independent mechanisms determine the loss of IGF2 imprinting (LOI), leading to biallelic IGF2 expression and enhanced bloodstream secretion levels in Wilms’ tumors and other tumor types including hepatoblastoma, glioma, testicular, colorectal cancers and others, driving malignant processes (please refer to [43,46]).